<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559568</url>
  </required_header>
  <id_info>
    <org_study_id>17808</org_study_id>
    <secondary_id>J2U-MC-YBAA</secondary_id>
    <nct_id>NCT04559568</nct_id>
  </id_info>
  <brief_title>A Study of LY3522348 in Healthy Participants</brief_title>
  <official_title>A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single- and Multiple-Ascending Doses of LY3522348 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study in healthy participants is to learn more about the safety of&#xD;
      LY3522348 and any side effects that might be associated with it. Blood tests will be&#xD;
      performed to check how much LY3522348 gets into the bloodstream and how long it takes the&#xD;
      body to eliminate it. This study has two parts: Part A will last up to about six weeks and&#xD;
      Part B will last up to about eight weeks for each participant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Actual">August 17, 2021</completion_date>
  <primary_completion_date type="Actual">August 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3522348</measure>
    <time_frame>Part A: Day 1 and Part B: Day 1 up to 144 hours post-last dose</time_frame>
    <description>PK: AUC of LY3522348</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of LY3522348</measure>
    <time_frame>Part A: Day 1 and Part B: Day 1 up to 144 hours post-last dose</time_frame>
    <description>PK: Cmax of LY3522348</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3522348 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3522348 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3522348 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3522348 administered orally. Some participants will also receive midazolam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally. Some participants will also receive midazolam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3522348</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3522348 (Part A)</arm_group_label>
    <arm_group_label>LY3522348 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered orally to some participants.</description>
    <arm_group_label>LY3522348 (Part B)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy as determined through medical evaluation including medical history&#xD;
             and physical examination&#xD;
&#xD;
          -  Have a body mass index of greater than or equal to (≥)18.5 and less than or equal to&#xD;
             (≤)40 kilograms per square meter (kg/m²)&#xD;
&#xD;
          -  Have had a stable weight for one month prior to screening and enrollment (less than&#xD;
             [&lt;]5 percent [%] body weight change) and have not received dietary intervention in the&#xD;
             one month prior to screening and enrollment&#xD;
&#xD;
          -  Have safety laboratory test results within normal reference range for the population&#xD;
             or investigative site, or results with acceptable deviations that are judged to be not&#xD;
             clinically significant by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the&#xD;
             opinion of the investigator, increases the risks associated with participating in the&#xD;
             study or may confound ECG data analysis&#xD;
&#xD;
          -  Have blood pressure of greater than (&gt;)160/90 millimeters of mercury (mmHg) and pulse&#xD;
             rate &lt;50 or &gt;100 beats per minute (bpm), supine (at screening), or with minor&#xD;
             deviations judged to be acceptable by the investigator&#xD;
&#xD;
          -  Have a history of fructosuria&#xD;
&#xD;
          -  Use of any drugs or substances that are known strong inducers or inhibitors of&#xD;
             cytochrome P450 3A4 (CYP3A) is specifically excluded within 14 days prior to the first&#xD;
             administration of study intervention and during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

